HALAVEN Solution for Injection
Eribulin mesylate
0.44 mg/ml
BAXALTA US Inc.
| Pack size | 1 Vial (2 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 1106.95 AED |
Indications
HALAVEN Solution for Injection is used for:
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Eribulin mesylate :
Mechanism of Action
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. [FDA]
Note
HALAVEN 0.44 mg/ml Solution for Injection manufactured by BAXALTA US Inc.. Its generic name is Eribulin mesylate. HALAVEN is availble in Saudi Arabia.
Farmaco SA drug index information on HALAVEN Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.